What Is Claimed Is:

5

10

15

20

- An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding the Neutrokine-alpha polypeptide having the complete amino acid sequence in Figures 1A and 1B (SEQ ID NO:2);
- (b) a nucleotide sequence encoding the Neutrokine-alpha polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC accession number 97768;
- (c) a nucleotide sequence encoding the Neutrokine-alpha polypeptide extracellular domain;
- (d) a nucleotide sequence encoding the Neutrokine-alpha polypeptide transmembrane domain;
- (e) a nucleotide sequence encoding the Neutrokine-alpha polypeptide intracellular domain;
- (f) a nucleotide sequence encoding a soluble Neutrokine-alpha polypeptide comprising the extracellular and intracellular domains but lacking the transmembrane domain; and
- (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e) or (f) above.
- 2. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence in Figures 1A and 1B (SEQ ID NO:1).
- 3. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in Figures 1A and 1B (SEQ ID NO:1) encoding the Neutrokine-alpha polypeptide having the complete amino acid sequence in Figures 1A and 1B (SEQ ID NO:2).

- 4. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding a soluble Neutrokine-alpha polypeptide comprising the extracellular domain shown in Figures 1A and 1B (SEQ ID NO:2).
- 5. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

5

10

15

20

25

- (a) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n-285 of SEQ ID NO:2, where n is an integer in the range of 2-190
- (b) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues 1-m of SEQ ID NO:2, where m is an integer in the range of 274-284;
- (c) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n-m of SEQ ID NO:2, where n and m are integers as defined respectively in (a) and (b) above; and
 - (d) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Neutrokine-alpha amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC accession number 97768, wherein said portion excludes from 1 to 190 amino acids from the amino terminus and from 1 to 11 amino acids from the C-terminus of said complete amino acid sequence.
 - 6. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in the deposit having ATCC accession number 97768.
 - 7. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the Neutrokine-alpha polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC accession number 97768.
 - 8. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding a soluble Neutrokine-alpha polypeptide comprising



the extracellular domain encoded by the cDNA clone contained in the deposit having ATCC accession number 97768.

An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e) or (f) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.

5

10

15

20

25

30

10. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a Neutrokine-alpha polypeptide having an amino acid sequence in (a), (b), (c), (d), (e) or (f) of claim 1.

- 11. The isolated nucleic acid molecule of claim 10, which encodes an epitope-bearing portion of a Neutrokine-alpha polypeptide selected from the group consisting of: a polypeptide comprising amino acid residues from about Phe-115 to about Leu-147 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ile-150 to about Tyr-163 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser-171 to about Phe-194 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Glu-223 to about Tyr-246 (SEQ ID NO:2); and a polypeptide comprising amino acid residues from about Ser-271 to about Phe-278 (SEQ ID NO:2).
- 12. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
 - 13. A recombinant vector produced by the method of claim 12.
- 14. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 13 into a host cell.
 - 15. A recombinant host cell produced by the method of claim 14.

- 16. A recombinant method for producing a Neutrokine-alpha polypeptide, comprising culturing the recombinant host cell of claim 15 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 17. An isolated Neutrokine-alpha polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

5

10

15

- (a) the amino acid sequence of the Neutrokine-alpha polypeptide having the complete amino acid sequence in Figures 1A and 1B (SEQ ID NO:2);
- (b) the amino acid sequence of the Neutrokine-alpha polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC accession number 97768;
- (c) the amino acid sequence of the Neutrokine-alpha polypeptide extracellular domain;
- (d) the amino acid sequence of the Neutrokine-alpha polypeptide transmembrane domain;
- (e) the amino acid sequence of the Neutrokine-alpha polypeptide intracellular domain;
- (f) the amino acid sequence of a soluble Neutrokine-alpha polypeptide comprising the domain; and
- (g) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d), (e) or (f).
- portion of the Neutrokine-alpha protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about Phe-115 to about Leu-147 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ile-150 to about Tyr-163 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser-171 to about Phe-194 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Glu-223 to about Tyr-246(SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser-271 to about Phe-278 (SEQ ID NO:2).

- 19. An isolated antibody that binds specifically to a Neutrokine-alpha polypeptide of claim 17.
- 20. A pharmaceutical composition comprising a polypeptide of claim 17 and a pharmaceutically acceptable carrier.
 - 21. An isolated polynucleotide encoding a modified Neutrokine-alpha protein, wherein, except for at least one conservative amino acid substitution, said modified peptide has an amino acid sequence that is identical to a member selected from the group consisting of:
 - (a) amino acids 1 to 285 of SEQ ID NO:2;

10

15

20

25

- (b) amino acids 2 to 285 of SEQ ID NO:2;
- (c) amino acids 1 to 46 of SEQ ID NO:2;
- (c) amino acids 47 to 72 of SEQ TO NO:2; and
- (c) amino acids 73 to 286 of SEQ ID NO:2.
- 22. A modified Neutrokine-alpha polypeptide molecule, wherein, except for at least one conservative amino acid substitution, said modified peptide has an amino acid sequence that is identical to a member selected from the group consisting of:
 - (a) amino acids 1 to 285 of SEQ ID NO:2;
 - (b) amino acids 2 to 285 of SEQ ID NO:2;
 - (c) amino acids 1 to 46 of SEQ ID NO:2;
 - (c) amino acids 47 to 72 of SEQ ID NO:2; and
 - (c) amino acids 73 to 286 of SEQ ID NO:2.
- 23. An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected selected from the group consisting of:
 - (a) the nucleotide sequence of SEQ ID NO:7;
 - (b) the nucleotide sequence of SEQ ID NO:8;
 - (c) the nucleotide sequence of SEQ ID NO:9;
- (d) the nucleotide sequence of a portion of the sequence shown in Figures 1A and 1B (SEQ ID NO:1) wherein said portion comprises at least 30 contiguous

nucleotide from nucleotide 1 to nucleotide 2442, excluding the sequence from nucleotide 1387 to 1421, the sequence from nucleotide 9 to 382, the sequence from nucleotide 1674 to 1996, the sequence from nucleotide 1401 to 1784, the sequence from nucleotide 900 to 1237, and any fragments located within these sequences; and

- (e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c) or (d) above.
- 24. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding the Neutrokine-alphaSV polypeptide having the complete amino acid sequence in Figures 5A and 5B (SEQ ID NO:19);
- (b) a nucleotide sequence encoding the Neutrokine-alphaSV polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the deposit having ATCC accession number 203518;
- (c) a nucleotide sequence encoding the Neutrokine-alphaSV polypeptide extracellular domain;
- (d) a nucleotide sequence encoding the Neutrokine-alphaSV polypeptide transmembrane domain;
- (e) a nucleotide sequence encoding the Neutrokine-alphaSV polypeptide intracellular domain;
- (f) a nucleotide sequence encoding a soluble Neutrokine-alphaSV polypeptide comprising the extracellular and intracellular domains but lacking the transmembrane domain; and
- (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e) or (f) above.
- 25. The isolated antibody of claim 19 wherein said isolated antibody inhibits binding of the protein of SEQ ID NO:2 to a Neutrokine-alpha receptor.

~ ld 121

and out of

30

5

10

15

20